As the New Year kicks off, so do weight loss resolutions—and right on cue, a new wave of GLP-1 medications has arrived, this time in pill form. Marketed as more convenient, more accessible, and easier than ever, these drugs are poised to open the floodgates for mass adoption. But behind the headlines is a familiar story: a high-stakes race for market share, billions in projected profits, and a pharmaceutical industry perfectly timed to capitalize on our collective desire for a fresh start. In today’s episode, I’m unpacking what the economic costs of GLP-1s really means—for patients, for the healthcare system, and perhaps for the future of weight loss and behavior change.

Are we manufacturing a new generation of lighter but weaker adults— in other words an epidemic of “thin frailty.”

Stay tuned I’ll unpack it in episode 15 from a PT perspective!

This episode is based on my recent article on Substack

Read and Listen to More on GLP

Tom Brady now a GLP ‘Chief Wellness officer’ at eMed-Episode 16 just released with this press announcement. (Oh boy, let’s Go?!?!)

This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit achievebalance.substack.com